Inhibition of vascular endothelial growth factor (VEGF) does not affect early renal changes in a rat model of lean type 2 diabetes

B. F. Schrijvers, A. S. De Vriese, Ronald Tilton, J. Van De Voorde, Larry Denner, N. H. Lameire, A. Flyvbjerg

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Type 2 diabetes is the most frequent cause of end-stage renal failure in many Western countries. Approximately 10-15% of all type 2 diabetics are lean. Various growth factors and cytokines have been implicated in the pathophysiology of diabetic kidney disease, including vascular endothelial growth factor (VEGF). To elucidate a role for VEGF in the renal changes associated with type 2 diabetes, we examined the effect of a VEGF-antibody (ab) on early renal changes in the Goto-Kakizaki (GK) rat, a lean type 2 diabetes model. GK-rats were treated for 6 weeks with the VEGF-ab or with an isotype-matched irrelevant IgG. Wistar rats were used as non-diabetic controls. Placebo-treated GK-rats showed a pronounced increase in glomerular volume and urinary albumin excretion (UAE) and no change in the renal expression of endothelial nitric oxide synthase (eNOS) compared to placebo-treated non-diabetic controls. Kidney weight and creatinine clearance were no different between the groups. VEGF-ab treatment had no effect on glomerular volume, UAE, eNOS expression, body weight, blood glucose levels or food intake, but lowered serum insulin levels in non-diabetic and diabetic animals. We conclude that VEGF inhibition has minimal effects on early renal changes in GK-rats.

Original languageEnglish (US)
Pages (from-to)21-25
Number of pages5
JournalHormone and Metabolic Research
Volume37
Issue number1
DOIs
StatePublished - Jan 2005

Fingerprint

Medical problems
Type 2 Diabetes Mellitus
Vascular Endothelial Growth Factor A
Rats
Kidney
Nitric Oxide Synthase Type III
Antibodies
Albumins
Placebos
Diabetic Nephropathies
Chronic Kidney Failure
Blood Glucose
Wistar Rats
Creatinine
Intercellular Signaling Peptides and Proteins
Animals
Eating
Immunoglobulin G
Body Weight
Insulin

Keywords

  • Endothelial nitric oxide synthase (eNOS)
  • Glomerular volume
  • Goto-Kakizaki (GK) rat
  • Kidney growth
  • VEGF-antibody (ab)

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Inhibition of vascular endothelial growth factor (VEGF) does not affect early renal changes in a rat model of lean type 2 diabetes. / Schrijvers, B. F.; De Vriese, A. S.; Tilton, Ronald; Van De Voorde, J.; Denner, Larry; Lameire, N. H.; Flyvbjerg, A.

In: Hormone and Metabolic Research, Vol. 37, No. 1, 01.2005, p. 21-25.

Research output: Contribution to journalArticle

Schrijvers, B. F. ; De Vriese, A. S. ; Tilton, Ronald ; Van De Voorde, J. ; Denner, Larry ; Lameire, N. H. ; Flyvbjerg, A. / Inhibition of vascular endothelial growth factor (VEGF) does not affect early renal changes in a rat model of lean type 2 diabetes. In: Hormone and Metabolic Research. 2005 ; Vol. 37, No. 1. pp. 21-25.
@article{ab22cf20fb034ca5b44933a9c127e81e,
title = "Inhibition of vascular endothelial growth factor (VEGF) does not affect early renal changes in a rat model of lean type 2 diabetes",
abstract = "Type 2 diabetes is the most frequent cause of end-stage renal failure in many Western countries. Approximately 10-15{\%} of all type 2 diabetics are lean. Various growth factors and cytokines have been implicated in the pathophysiology of diabetic kidney disease, including vascular endothelial growth factor (VEGF). To elucidate a role for VEGF in the renal changes associated with type 2 diabetes, we examined the effect of a VEGF-antibody (ab) on early renal changes in the Goto-Kakizaki (GK) rat, a lean type 2 diabetes model. GK-rats were treated for 6 weeks with the VEGF-ab or with an isotype-matched irrelevant IgG. Wistar rats were used as non-diabetic controls. Placebo-treated GK-rats showed a pronounced increase in glomerular volume and urinary albumin excretion (UAE) and no change in the renal expression of endothelial nitric oxide synthase (eNOS) compared to placebo-treated non-diabetic controls. Kidney weight and creatinine clearance were no different between the groups. VEGF-ab treatment had no effect on glomerular volume, UAE, eNOS expression, body weight, blood glucose levels or food intake, but lowered serum insulin levels in non-diabetic and diabetic animals. We conclude that VEGF inhibition has minimal effects on early renal changes in GK-rats.",
keywords = "Endothelial nitric oxide synthase (eNOS), Glomerular volume, Goto-Kakizaki (GK) rat, Kidney growth, VEGF-antibody (ab)",
author = "Schrijvers, {B. F.} and {De Vriese}, {A. S.} and Ronald Tilton and {Van De Voorde}, J. and Larry Denner and Lameire, {N. H.} and A. Flyvbjerg",
year = "2005",
month = "1",
doi = "10.1055/s-2005-861027",
language = "English (US)",
volume = "37",
pages = "21--25",
journal = "Hormone and Metabolic Research",
issn = "0018-5043",
publisher = "Georg Thieme Verlag",
number = "1",

}

TY - JOUR

T1 - Inhibition of vascular endothelial growth factor (VEGF) does not affect early renal changes in a rat model of lean type 2 diabetes

AU - Schrijvers, B. F.

AU - De Vriese, A. S.

AU - Tilton, Ronald

AU - Van De Voorde, J.

AU - Denner, Larry

AU - Lameire, N. H.

AU - Flyvbjerg, A.

PY - 2005/1

Y1 - 2005/1

N2 - Type 2 diabetes is the most frequent cause of end-stage renal failure in many Western countries. Approximately 10-15% of all type 2 diabetics are lean. Various growth factors and cytokines have been implicated in the pathophysiology of diabetic kidney disease, including vascular endothelial growth factor (VEGF). To elucidate a role for VEGF in the renal changes associated with type 2 diabetes, we examined the effect of a VEGF-antibody (ab) on early renal changes in the Goto-Kakizaki (GK) rat, a lean type 2 diabetes model. GK-rats were treated for 6 weeks with the VEGF-ab or with an isotype-matched irrelevant IgG. Wistar rats were used as non-diabetic controls. Placebo-treated GK-rats showed a pronounced increase in glomerular volume and urinary albumin excretion (UAE) and no change in the renal expression of endothelial nitric oxide synthase (eNOS) compared to placebo-treated non-diabetic controls. Kidney weight and creatinine clearance were no different between the groups. VEGF-ab treatment had no effect on glomerular volume, UAE, eNOS expression, body weight, blood glucose levels or food intake, but lowered serum insulin levels in non-diabetic and diabetic animals. We conclude that VEGF inhibition has minimal effects on early renal changes in GK-rats.

AB - Type 2 diabetes is the most frequent cause of end-stage renal failure in many Western countries. Approximately 10-15% of all type 2 diabetics are lean. Various growth factors and cytokines have been implicated in the pathophysiology of diabetic kidney disease, including vascular endothelial growth factor (VEGF). To elucidate a role for VEGF in the renal changes associated with type 2 diabetes, we examined the effect of a VEGF-antibody (ab) on early renal changes in the Goto-Kakizaki (GK) rat, a lean type 2 diabetes model. GK-rats were treated for 6 weeks with the VEGF-ab or with an isotype-matched irrelevant IgG. Wistar rats were used as non-diabetic controls. Placebo-treated GK-rats showed a pronounced increase in glomerular volume and urinary albumin excretion (UAE) and no change in the renal expression of endothelial nitric oxide synthase (eNOS) compared to placebo-treated non-diabetic controls. Kidney weight and creatinine clearance were no different between the groups. VEGF-ab treatment had no effect on glomerular volume, UAE, eNOS expression, body weight, blood glucose levels or food intake, but lowered serum insulin levels in non-diabetic and diabetic animals. We conclude that VEGF inhibition has minimal effects on early renal changes in GK-rats.

KW - Endothelial nitric oxide synthase (eNOS)

KW - Glomerular volume

KW - Goto-Kakizaki (GK) rat

KW - Kidney growth

KW - VEGF-antibody (ab)

UR - http://www.scopus.com/inward/record.url?scp=13944274471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13944274471&partnerID=8YFLogxK

U2 - 10.1055/s-2005-861027

DO - 10.1055/s-2005-861027

M3 - Article

C2 - 15702434

AN - SCOPUS:13944274471

VL - 37

SP - 21

EP - 25

JO - Hormone and Metabolic Research

JF - Hormone and Metabolic Research

SN - 0018-5043

IS - 1

ER -